A hazard ratio was estimated by a ratio of median survival times, but with considerable uncertainty

被引:17
作者
Cortes, Jordi [1 ]
Gonzalez, Jose A. [1 ]
Campbell, Michael J. [2 ]
Cobo, Erik [1 ]
机构
[1] UPC BarcelonaTech, Dept Stat & Operat Res, Barcelona, Spain
[2] Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England
关键词
Hazard ratio; Median ratio; Concordance; Survival; Clinical trial; Cancer; CETUXIMAB;
D O I
10.1016/j.jclinepi.2014.05.017
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To evaluate the empirical concordance between the hazard ratio (HR) and the median ratio (MR) in survival cancer studies. Study Design and Setting: We selected all cancer survival articles from the New England Journal of Medicine published between 2000 and 2010. The qualitative concordance was estimated by the proportion of measured pairs in which the treatment effects for the MR and HR are in the same direction. The quantitative concordance was assessed through (1) the mean difference between the logarithms of the measures, (2) the Lin coefficient, and (3) the Bland-Altman plot. Results: We retrieved 106 measured pairs (HR-MR) corresponding to 54 articles. Concordance was high, at both the qualitative (99 of 106, 93.4%) and quantitative levels (mean MR-to-HR ratio, 1.01; 95% confidence interval: 0.95, 1.06). However, the 95% Bland-Altman discordance limits indicate that the MR can be up to 50% higher or 50% lower than the HR. Conclusion: The average concordance allows ttialists to approximate HR from MR to determine sample size. However, the discordance limits are too great to consider that both measures are interchangeable. The actual policy to report HR only is not enough. Our results emphasize the need to attach descriptive survival measures to the HR. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:1172 / 1177
页数:6
相关论文
共 21 条
[1]   REVIEW OF SURVIVAL ANALYSES PUBLISHED IN CANCER JOURNALS [J].
ALTMAN, DG ;
DESTAVOLA, BL ;
LOVE, SB ;
STEPNIEWSKA, KA .
BRITISH JOURNAL OF CANCER, 1995, 72 (02) :511-518
[2]  
[Anonymous], NEW ENGL J MED
[3]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[4]   On the use and utility of the Weibull model in the analysis of survival data [J].
Carroll, KJ .
CONTROLLED CLINICAL TRIALS, 2003, 24 (06) :682-701
[5]   Interpreting measures of treatment effect in cancer clinical trials [J].
Case, LD ;
Kimmick, G ;
Paskett, ED ;
Lohman, K ;
Tucker, R .
ONCOLOGIST, 2002, 7 (03) :181-187
[6]   The effect of group psychosocial support on survival in metastatic breast cancer. [J].
Goodwin, PJ ;
Leszcz, M ;
Ennis, M ;
Koopmans, J ;
Vincent, L ;
Guther, H ;
Drysdale, E ;
Hundleby, M ;
Chochinov, HM ;
Navarro, M ;
Speca, M ;
Hunter, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (24) :1719-1726
[7]   The Hazards of Hazard Ratios [J].
Hernan, Miguel A. .
EPIDEMIOLOGY, 2010, 21 (01) :13-15
[8]   Cetuximab for the treatment of colorectal cancer [J].
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Karapetis, Christos S. ;
Zalcberg, John R. ;
Tu, Dongsheng ;
Au, Heather-Jane ;
Berry, Scott R. ;
Krahn, Marianne ;
Price, Timothy ;
Simes, R. John ;
Tebbutt, Niall C. ;
van Hazel, Guy ;
Wierzbicki, Rafal ;
Langer, Christiane ;
Moore, Malcolm J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2040-2048
[9]   K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].
Karapetis, Christos S. ;
Khambata-Ford, Shirin ;
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Tu, Dongsheng ;
Tebbutt, Niall C. ;
Simes, R. John ;
Chalchal, Haji ;
Shapiro, Jeremy D. ;
Robitaille, Sonia ;
Price, Timothy J. ;
Shepherd, Lois ;
Au, Heather-Jane ;
Langer, Christiane ;
Moore, Malcolm J. ;
Zalcberg, John R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765
[10]  
King T S, 2001, J Biopharm Stat, V11, P83, DOI 10.1081/BIP-100107651